These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 22942310)

  • 21. Drug Insight: abatacept for the treatment of rheumatoid arthritis.
    Ruderman EM; Pope RM
    Nat Clin Pract Rheumatol; 2006 Dec; 2(12):654-60. PubMed ID: 17133250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ulcerative colitis during CTLA-4Ig therapy in a patient with rheumatoid arthritis.
    Amezcua-Guerra LM; Hernández-Martínez B; Pineda C; Bojalil R
    Gut; 2006 Jul; 55(7):1059-60. PubMed ID: 16766771
    [No Abstract]   [Full Text] [Related]  

  • 23. Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion.
    Walker UA; Courvoisier DS; Dudler J; Aeberli D; von Kempis J; Scherer A; Finckh A;
    Rheumatology (Oxford); 2011 Jan; 50(1):243-4. PubMed ID: 20716674
    [No Abstract]   [Full Text] [Related]  

  • 24. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig.
    Knoerzer DB; Karr RW; Schwartz BD; Mengle-Gaw LJ
    J Clin Invest; 1995 Aug; 96(2):987-93. PubMed ID: 7543497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abatacept-induced psoriasis.
    Silverman D; Oliver A
    Cutis; 2011 Sep; 88(3):117-8. PubMed ID: 22017062
    [No Abstract]   [Full Text] [Related]  

  • 26. Use of abatacept in eosinophilic asthma.
    Abdelshaeed R; Griffiths GB; Neighbour H
    J Allergy Clin Immunol Pract; 2014; 2(2):220-1. PubMed ID: 24607053
    [No Abstract]   [Full Text] [Related]  

  • 27. Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept.
    Germanidis G; Hytiroglou P; Zakalka M; Settas L
    J Hepatol; 2012 Jun; 56(6):1420-1. PubMed ID: 22127282
    [No Abstract]   [Full Text] [Related]  

  • 28. Psoriasiform drug eruption due to abatacept.
    Kato K; Satoh T; Nishizawa A; Yokozeki H
    Acta Derm Venereol; 2011 May; 91(3):362-3. PubMed ID: 21336469
    [No Abstract]   [Full Text] [Related]  

  • 29. Abatacept as add-on therapy for rheumatoid arthritis.
    Allison C
    Issues Emerg Health Technol; 2005 Sep; (73):1-4. PubMed ID: 16317826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection.
    Fanouriakis A; Vassilopoulos D; Repa A; Boumpas DT; Sidiropoulos P
    Rheumatology (Oxford); 2014 Jan; 53(1):195-6. PubMed ID: 23771951
    [No Abstract]   [Full Text] [Related]  

  • 31. [Fusion protein abatacept. Remission in every 5th TNF-alpha refractory patient].
    MMW Fortschr Med; 2008 Jun; 150(26-27):56-7. PubMed ID: 18683309
    [No Abstract]   [Full Text] [Related]  

  • 32. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry.
    Gottenberg JE; Ravaud P; Cantagrel A; Combe B; Flipo RM; Schaeverbeke T; Houvenagel E; Gaudin P; Loeuille D; Rist S; Dougados M; Sibilia J; Le Loët X; Marcelli C; Bardin T; Pane I; Baron G; Mariette X
    Ann Rheum Dis; 2012 Nov; 71(11):1815-9. PubMed ID: 22615458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methotrexate-induced lung injury in patients with rheumatoid arthritis occurs with peripheral blood lymphocyte count decrease.
    Inokuma S; Kono H; Kohno Y; Hiramatsu K; Ito K; Shiratori K; Yamazaki J; Nakayama H; Shoda H; Tanaka Y
    Ann Rheum Dis; 2006 Aug; 65(8):1113-4. PubMed ID: 16837494
    [No Abstract]   [Full Text] [Related]  

  • 34. Abatacept use in rheumatoid arthritis: evidence review and recommendations.
    Martín Mola E; Balsa A; Martínez Taboada V; Sanmartí R; Marenco JL; Navarro Sarabia F; Gómez-Reino J; Alvaro-Gracia JM; Román Ivorra JA; Lojo L; Plasencia C; Carmona L;
    Reumatol Clin; 2013; 9(1):5-17. PubMed ID: 22766432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abatacept therapy for rheumatoid arthritis in the setting of hepatitis C infection.
    Mahajan TD; Hooker R; Maher L; Brown G; Reimold A
    J Clin Rheumatol; 2010 Oct; 16(7):332-4. PubMed ID: 20859223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two cases of ulcerative colitis developing in rheumatoid arthritis patients during abatacept therapy.
    Motohashi R; Ikeuchi H; Hiromura K; Ohishi Y; Sakurai N; Sakairi T; Kaneko Y; Maeshima A; Nojima Y
    Scand J Gastroenterol; 2014 Oct; 49(10):1270-1. PubMed ID: 25115461
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 3. T-cell costimulation blocker].
    Kohsaka H
    Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2979-84. PubMed ID: 22175141
    [No Abstract]   [Full Text] [Related]  

  • 38. Role of abatacept in the management of rheumatoid arthritis.
    Nogid A; Pham DQ
    Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Orencia approved for rheumatoid arthritis.
    Health News; 2006 Mar; 12(3):2. PubMed ID: 16535763
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
    Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
    Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.